Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Rifaximin for Covert Hepatic Encephalopathy
NCT03077217Phase 4Completed
- Sponsor
- Shanghai Changzheng Hospital
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in covert hepatic encephalopathy (CHE), sponsored by Shanghai Changzheng Hospital. Started May 2017; status: completed.
02
Drugs
rifaximin
03
Conditions
covert hepatic encephalopathy (CHE)
Beyond the preview
Go deeper on NCT03077217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077217.